|
Novel Main Protease Inhibitors as SARS-CoV-2 Antivirals
This technology encompasses the development of novel inhibitors for the main protease, or Mpro, of SARS-CoV-2. The main protease of SARS-CoV-2 is a validated drug target and could be key to the development of antiviral drugs against the virus. The inhibitors proposed in this technology are notable, as they are potent main protease inhibitors with high...
Published: 2/2/2024
|
Inventor(s): Jun Wang
Keywords(s):
Category(s): Technology Classifications > Life Sciences
|
|
A Novel Pan-T-Type Calcium Channel Modulator that alleviates Tonic, Neuropathic and Inflammatory Pain
This invention describes a non-opioid method to treat pain using a novel T-type calcium channel blocker.
Background:
Current treatments for many types of pain typically include opioid painkillers, which pose a significant risk of addiction and overdose in patients, creating a demand for a treatment with less risk and less side-effects. In neuropathic,...
Published: 11/16/2023
|
Inventor(s): Rajesh Khanna, Jun Wang
Keywords(s):
Category(s): Technology Classifications, Technology Classifications > Life Sciences > Drug Delivery, Technology Classifications > Life Sciences > Small Molecules
|
|
Discovery of Pyrazolopyridine Analogs as Broad-Spectrum Antivirals against Non-Polio Enteroviruses including EV-D68, EVÂA71, and CVB3
This invention reports the discovery and development of pyrazolopyridine inhibitors that have been shown to be effective in cell culture against multiple strains of non-polio enteroviruses including: EV-D68, EVA71, and CVB3. There are currently no antivirals or vaccines for non-polio enteroviruses, and the health consequences of infection for some...
Published: 1/10/2024
|
Inventor(s): Jun Wang, Naoya Kitamura
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Healthcare Portfolios > Infectious Diseases
|
|
PLpro Inhibitors Against SARS-CoV-2
There are two cysteine proteases that are encoded by SARS-CoV-2, the main protease (Mpro) and the papain-like protease (PLpro). Both of these proteases have been shown to be essential in viral replication and are validated antiviral drug targets. PLpro cleaves the viral SARS-CoV-2 polyprotein at three sites. In addition, it modulates host immune response...
Published: 11/16/2023
|
Inventor(s): Jun Wang, Chunlong Ma, Naoya Kitamura, Yanmei Hu
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Small Molecules
|
|
Discovery of Non-Covalent Inhibitors Targeting the SARS-CoV-2 Main Protease
This technology encompasses the development of novel inhibitors for the main protease, or Mpro, of SARS-CoV-2. The main protease of SARS-CoV-2 is a validated drug target and could be key to the development of more antiviral drugs against the virus. The inhibitors proposed in this technology are notable, as they are non-covalent inhibitors with high...
Published: 11/16/2023
|
Inventor(s): Jun Wang, Naoya Kitamura, Chunlong Ma
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Infectious Diseases
|
|
Discovery of T-Type Calcium Channel Antagonist from Multicomponent Reactions and their Application in Paclitaxel-Induced Peripheral Neuropathy
This invention uses innovative selective T-type antagonists in order to ease pain involved with chemotherapy-induced peripheral neuropathy (CIPN).
Background:
Chemotherapy remains a frontline treatment for many forms of cancer, however, chemotherapy agents commonly cause severe side effects such as CIPN. While opioids have been used to manage CIPN,...
Published: 11/16/2023
|
Inventor(s): Jun Wang, Rajesh Khanna
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Therapeutics
|
|
Bioactive Compounds for Use in Inhibiting SARS-CoV-2 Viral Replication
University of Arizona inventors have discovered inhibitors targeting the SARS-CoV-2 main protease. These inhibitors have potential for use as therapeutics against COVID-19 as well as other SARS and MERS strains.
Background:
Viral outbreaks are not new; we have faced SARS, MERS, Nipah, Zika, and several other viral outbreaks in recent history. In late...
Published: 11/16/2023
|
Inventor(s): Jun Wang, Chunlong Ma
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Therapeutics
|
|
Broad-Spectrum Antivirals Against Enterovirus D68, A71, and Coxsackievirus B3
This invention is a set of compounds which have antiviral activity against the enteroviruses D68, A71, and coxsackievirus B3. They can be used both prophylactically, to prevent infection, and therapeutically, to treat it.
Background:
Enteroviruses are a group of viruses that belong to the Picornaviridae family. One enterovirus, the polio virus,...
Published: 11/16/2023
|
Inventor(s): Jun Wang, Rami Musharrafieh, Chunlong Ma, Jiantao Zhang, Yanmei Hu
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios, Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Therapeutics
|
